This Dow Stock's Gains May Not Be Finished Yet

Last week, the Dow Jones Industrial Average (DJINDICES: ^DJI  ) ended up 0.09% at 15,559 points after hitting an all-time high Tuesday. The S&P 500 (SNPINDEX: ^GSPC  ) trailed Mr. Jones early in the week but managed to retake some of its gains for an overall 0.23% dip.

^DJI data by YCharts.

Sticky earnings
The last Dow stock to announce earnings last week was 3M (NYSE: MMM  ) , which reported on Thursday. The company missed on the top line but made up for it with slightly better-than-expected net income. 3M's $7.75 billion in revenue came in $20 million below estimates, but EPS added an extra penny to analyst predictions. Expectations aside, sales are up a seasonally adjusted 2.9%, while EPS rose 3%.

Management pointed to overall economic conditions as a continued drag on 3M's operations, but they have high expectations for increased demand in the coming quarters. Shares edged up 0.78% last week and have been boosted 12.6% over the last three months.

Macro Monday
Two macro reports hit the press today at 10 a.m. EDT. Pending home sales for June will add another data point to the housing market's recovery moves, although analysts are predicting a 1.4% drop after May's 6.7% rise, hitting levels unseen since 2006. New-home sales hit a recovery high last week, but ballooning home prices have some analysts worried about a "supply squeeze" bubble.

Investors will also get a taste of manufacturing's latest moves from the Dallas Fed Manufacturing Survey. Although this questionnaire is limited to the Lone Star State, analysts keep a close watch on regional manufacturing as a sign of overall economic improvement. The survey showed a positive perspective for June following a pessimistic April and May. Mr. Market expects manufacturers to keep their optimism up in July, with increasing new orders and company outlooks painting a pretty picture for Texas' future.

Monday movers
Coming up on the earnings calendar today are American Capital Agency (NASDAQ: AGNC  ) and Herbalife (NYSE: HLF  ) , both reporting after market close.

American Capital is an mREIT (mortgage real-estate investment trust) with massive growth in recent years, but rising interest rates could put this stock on the chopping block. The company (and most other mREITS) have taken a dip in the past quarter, with American Capital shares down 34% in the last three months. According to Fool David Hanson, that means this earnings report may not be the big market-mover it could otherwise have been. Analysts aren't expecting much, but investors should keep a close watch to make sure the company's losses don't leave it overextended.

Likewise, Herbalife has seen its own shares rise and fall not on earnings reports, but on positive and pessimistic views expressed by prominent investors Carl Icahn and Bill Ackman, respectively. The company has consistently beaten earnings estimates over the past year, and shares are up a whopping 50.8% in the last three months. Wise investors will tune out Herbalife's stock market soap opera and focus on the fundamentals that count.

That's exactly what we do here at the Fool, and it has helped our analysts (and subscribers) make some of the smartest stock picks around. The Motley Fool's chief investment officer has selected his No. 1 stock for this year. Find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2013." Just click here to access the report and find out the name of this under-the-radar company.

Facebook Video Ads Are Coming to a Feed Near You

Considering that Facebook (NASDAQ: FB  ) served over 557 million videos to its U.S. users in February, it's only a matter of time until the social network starts monetizing this untapped revenue stream. According to AdAge, Facebook is currently finalizing video ad formats, and is on track to go live with embedded video advertisements by June or July. Although Facebook has gained the reputation that its advertising platform is "cheap," these video slots are expected to fetch top dollar. Facebook is hoping to bring in close to $1 million for a daily run of a 15-second slot. In other words, Facebook is hoping its massive scale can tap into fat-cat TV advertising budgets.

Outcries to follow
Whenever Facebook makes a sweeping change to the user experience, the company runs the risk of damaging its reputation with users. Facebook has to find that difficult to define balance between high user engagement and monetization levels. AdAge believes Facebook will limit video ad frequency per user to no more than three per day, which would show the world (and investors) that Facebook isn't willing to structurally damage the user experience.

Living proof
Google's  (NASDAQ: GOOG  ) YouTube is living proof that video advertising can be done effectively without detracting from the user experience. In February alone, YouTube served over 2.2 billion ads to 150.7 million U.S. viewers. Yes, you read that right -- YouTube served 2.2 billion video ads out of a possible 11.3 billion videos streamed by U.S. viewers. With these kinds of numbers, it's hard to argue against Facebook wanting to monetize the videos to its one billion-plus worldwide user base.

Where it matters most
To be a long-term investor in Facebook, you must have a high degree of confidence that the company is on the right track in mobile, because more than 60% of its users access the site on a mobile device. Video ads could prove to be a tremendously effective way to drive cross-platform monetization, regardless of whether the user engages on the desktop or mobile version of the site.

Now, the bigger question is whether those deep-pocketed TV advertisers will get behind Facebook's vision. With General Motors back on the Facebook wagon, the timing couldn't be any better for Facebook to catch a few whales.

After the world's most hyped IPO turned out to be a dunce, most investors probably don't even want to think about shares of Facebook. But there are things every investor needs to know about this company. We've outlined them in our newest premium research report. There's a lot more to Facebook than meets the eye, so read up on whether there is anything to "like" about it today, and we'll tell you whether we think Facebook deserves a place in your portfolio. Access your report by clicking here.

4 Key Takeaways From Embraer Earnings

Before last Friday, Embraer (NYSE: ERJ  ) stock was the beneficiary of keen investor enthusiasm, having gained more than 36% year to date. After a shaky week of trading and a sell-off on Friday, Embraer's stock is now up but 24% year to date. A negatively received earnings report catalyzed Friday's selling angst. Let's review a few key themes that rose to the surface of Embraer's second-quarter 2013 earnings release.

Analysts and investors were caught off guard by deferred tax issues
Embraer follows international financial reporting standards, or IFRS, when reporting its earnings. IFRS is on the whole similar to U.S. generally accepted accounting principles, or GAAP, but differences in the treatment of certain accounting issues can occasionally cause wide variances in reported numbers between the two systems.

Embraer experienced one of those moments this week, when most analysts' expectations for earnings disregarded the effect that the recent slide in the Brazilian currency, the real, would have on deferred taxes. Essentially, by IFRS requirements, Embraer had to revalue the tax basis of some of its non-monetary assets such as inventory and fixed assets because of currency differences, and consequently took a non-cash charge of $97.1 million against earnings. The revaluation turned a $91.8 million profit into a $5.3 million loss. 

Deferred tax issues are often timing issues, and non-cash charges like this can often set up favorable comparisons in the same quarter the following year. The gist of this charge is that Embraer now has a deferred tax liability on its balance sheet that investors should keep an eye on for the next few quarters.

Total deliveries were down
Embraer delivered 29 executive jets (small jets purchased by private corporations) to customers in the second quarter of 2013, which increased significantly over the prior year, in which the company saw 23 deliveries.Commercial jet deliveries decreased, however, from 35 jets delivered in the second quarter of 2012 to 22 jets delivered in Q2 2013. If there was a reason to be disappointed in this earnings report, it was the pace of production. So far this year, the company has delivered 80 total planes. Management affirmed that total deliveries for the year will land somewhere between 195 and 215 total planes, so the third and fourth quarters promise to be busy, as Embraer will have to produce at roughly 1.5 times the production rate of the first half of the year to meet the low end of its guidance.

The backlog is vibrant
As expected from the closing a number of deals in its E-Jets series during the quarter, Embraer's backlog grew handsomely, from $13.3 billion at the end of Q1 2013 to $17.1 billion at the close of Q2 2013 -- a 29% increase.According to CFO Jose Filippo, the backlog has reached 2009 levels. With the backlog being driven by an uptick in commercial jet orders, the company will do well to push as much production in this area as possible, especially as demand for the executive jet series appears soft, because of the unexpected economic slowdown in Brazil and China, which are primary markets for Embraer's private jets.

Embraer attacks a Boeing/Airbus stranglehold
One of the nuggets that came out of this transcript was Embraer's intention to take on more sales to aircraft lessors (companies that purchase planes and lease them to airlines). This is a market historically dominated by Boeing (NYSE: BA  ) and European Aeronautical Defense and Space's  (NASDAQOTH: EADSY  ) Airbus.Earlier this month, Embraer announced that it had won an order for 50 E-Jets series planes from leasing giant International Lease Finance, with options to deliver 50 more.

On Embraer's earnings call, CEO Frederico Curado noted that Boeing and Airbus have up to 35% of their respective backlogs committed to aircraft lessors, and that Embraer intends to raise its current level of 16%-20% of sales to lessors closer to the percentages enjoyed by its much larger peers.This is a shrewd move for Embraer, as its popular E-Jet series, a smaller commercial airplane with a sweet spot of around 75 seats, is sought after by major domestic airlines, but also smaller regional airlines that may be more inclined to use lessors in building their fleets versus the higher upfront costs of purchasing directly.

5 Best Stocks To Buy Right Now

What to make of this earnings release
While the production rate in the first half of the year leaves something to be desired, Embraer is enjoying great demand from regional airlines for its commercial jets. With a robust backlog, the company should be able to focus on speeding up deliveries and finding a few percentage points of margin from productivity initiatives currently under way. If you hold Embraer, you'll want to monitor plane deliveries for the back half of the year over the next two quarters. For now, Embraer remains a great, thematic long-term play in the airline manufacturing industry.

A big Embraer competitor -- and more
With the American markets reaching new highs, investors and pundits alike are skeptical about future growth. They shouldn't be. Many global regions are still stuck in neutral, and their resurgence could result in windfall profits for select companies. A recent Motley Fool report, "3 Strong Buys for a Global Economic Recovery," outlines three companies that could take off when the global economy gains steam. Click here to read the full report!

2 Good Coal Stocks to Invest In

Coal stocks have been under constant pressure since the financial crisis. Most are trading at a fraction of pre-crisis value which has some investors wondering if the value of these stocks has plunged too far, making now a good time to invest in a rebound in coal. As you can see from the chart below, the performance has been absolutely abysmal:

CNX data by YCharts

If that chart has you seeing opportunity instead of failure then I have good news for you. Among the group, I see two coal stocks with business models that set them apart from the group and give them an edge. If you are looking to invest in coal, these are the two stocks worth digging into if you want to play the future rebound of coal.

The global pure-play: Peabody Energy (NYSE: BTU  )
With a leading presence in Australia, the southern Powder River Basin and the Illinois Basin, Peabody has the best assets to access the world export markets. That's vitally important because while coal might not be all that popular here in the U.S., Pacific Rim markets such as India and China are expected to import record coal volumes this year. Overall, seaborne thermal coal demand is likely to increase 50 million tonnes on growing Asian demand. The following slide really sums up coal demand from those two key Asian countries.

Source: Peabody Energy Investor Presentation (link opens a PDF)

Peabody is ahead of its U.S.-based peers in tapping this demand. First, it acquired coal operations in Australia, which places it closer to its customers. In addition to that, it's been active in securing long-term export capacity in the U.S. Last year it signed a deal with Kinder Morgan Partners (NYSE: KMP  ) to increase its export capacity to more than 7 million tons of coal per year from Kinder Morgan's Houston terminal. Overall, Kinder Morgan is adding to its coal export capacity in Louisiana as well as considering a coal export terminal at its existing bulk facility in Charleston, S.C. The clear trend here is that access to export markets is important to coal producers. 

Peabody isn't the only company with access to export markets. Arch Coal (NYSE: ACI  ) for example also has coal export deals with Kinder Morgan while Alpha Natural Resources (NYSE: ANR  )  has tremendous access to the export markets. The difference here is that all of Peabody's reserves are in the lower-cost Powder River and Illinois basins, while both Arch and Alpha have higher-cost Appalachian coal operations which cut into margins. That's why I think Peabody really has an advantage here because when you combine its low-cost coal reserves with its access to export markets, as well as its Australian coal operations, it has all the makings of a really good stock to invest in relative to these peers.

If you can't beat them, join them: CONSOL Energy (NYSE: CNX  )
The reason why coal has been under so much pressure in the U.S. is that natural gas is pushing its way into coal's core electricity market. This is where CONSOL's diversification into natural gas gives it a leg up because it can benefit from increased natural gas demand by utilities. Because of current market conditions, CONSOL is all but abandoning its efforts to grow coal production in the future and instead will look to grow its gas business by double digits.

CONSOL is still a top-tier coal miner; it has some coal growth ahead thanks to its soon to be finished BMX Mine, which is expected to deliver 5 million tons of coal per year. Further, the company has access to export capacity through its 100%-owned Baltimore terminal which is undergoing an expansion of its capacity to 16 million tons. The bottom line here, and what makes CONSOL a good stock to invest in, is its balanced approach which, when combined with its strong balance sheet, really sets it apart.

Final Foolish thoughts
Of the two, I think Peabody is the company worth digging deeper into first as its Australian operations really give it a major competitive advantage. While I like that CONSOL is diversified, natural gas is also a pretty cheap commodity these days which doesn't help margins very much. Further, coal from Baltimore has a much longer journey ahead of it to reach Asia than does coal from Australia, which is a good reason to dig deeper into Peabody's stock as a potential investment.

If you would like to dig a little deeper into Peabody and its position in the export market as well as its ability to capitalize on a rebound in the U.S. coal market, The Motley Fool has authored a special new premium report detailing exactly why Peabody Energy is perhaps most worthy of your consideration. Don't miss out on this invaluable resource -- simply click here now to claim your copy today.

A Fool Looks Back

Yahoo! (NASDAQ: YHOO  ) and Google (NASDAQ: GOOG  ) reported quarterly results this week. The market enjoyed Yahoo!'s performance and soured when Google came to the plate, but both companies offered similar snapshots of the challenge in monetizing mobile.

Google is growing faster. Yahoo! moved higher largely on the increasing value of its Chinese investments. However, both companies are struggling with the falling rate of revenue per click. That's not a surprise. Advertisers aren't going to spend as much on mobile platforms as they do desktop search queries. It's harder to close a sale or generate a lead from someone who clicks on an ad from a phone or a tablet.

One good thing we can say about clunky desktop keyboards is that they do make typing easier than pecking on a small smartphone screen or the compact tablet keyboards out there.

Thankfully, Google and Yahoo! are making up the difference in volume. Revenue per click is down, but paid clicks in general are on the rise. We still have a long way to go until a mobile ad will be as valuable as a PC ad, but the end result, for now, will do.

Briefly in the news
And now let's take a quick look at some of the other stories that shaped our week.

Shares of Chipotle Mexican Grill (NYSE: CMG  ) hit a new 52-week high after posting stronger revenue than analysts were expecting. The burrito roller also indicated that menu price increases are on the way in a move that will increase margins. Netflix (NASDAQ: NFLX  ) also landed a fresh 52-week high, but it doesn't report until next week. The big push for the leading video service was a dozen Emmy nominations for House of Cards and Arrested Development. There's always a model-affirming Emmy nod in the banana stand. Inteliquent (NASDAQ: IQNT  ) moved sharply higher after jacking up its revenue and adjusted EBITDA targets for the year. The provider of wholesale voice services had hosed down its outlook in May.

Getting ready for big changes in 2014
Obamacare will undoubtedly have far-reaching effects. The Motley Fool's new free report "Everything You Need to Know About Obamacare" lets you know how your health insurance, your taxes, and your portfolio could be affected. Click here to read more. 

As Mortgage Rates Rise, Will Panic Buying Ensue?

Rising mortgage interest rates are going to slow down the red-hot mortgage market, right? Well, according to the National Association of Realtors, maybe not. The national trade group of real estate professionals thinks the recent spike in mortgage rates may be just the thing to bring hesitant buyers off the fence and to the closing table.

As backwards as it sounds, could higher prices really translate to higher mortgage sales? In the video below, Motley Fool contributor Jay Jenkins takes a closer look at the implications of such a phenomena for mortgage lenders like Wells Fargo (NYSE: WFC  ) , JPMorgan Chase (NYSE: JPM  ) , and Bank of America (NYSE: BAC  ) .

Despite many banks raking in mortgage fees over the past several years, some investors are terrified about investing in big banking stocks after the crash, but the sector has one notable stand-out. In a sea of mismanaged and dangerous peers, it rises above as "The Only Big Bank Built to Last." You can uncover the top pick that Warren Buffett loves in The Motley Fool's new report. It's free, so click here to access it now.

 

Best Stocks To Buy For 2014

What to Watch Now? Ask Your App!

As Foolish investors, we're always looking for companies with some sort of competitive advantage, or moat.

TiVo (NASDAQ: TIVO  ) has operated in a cutthroat industry since its inception. As Verizon, DIRECTV, and others began to offer their own DVRs, TiVo's subscriber count plummeted.

One way management hopes to reverse that trend is by building a technological advantage over these cable and satellite operators. The company recently introduced improvements to its Apple iOS app with the addition of "What to Watch Now" -- available to owners of one of the TiVo Premiere DVRs. TiVo's Jim Denney chatted about the app with Motley Fool analyst Rex Moore at the recent Cable Show in Washington, D.C. In part two of this series, Jim shows how the app can be used to find movies, kids' shows, and other programming tailored to the viewer.

The television landscape is changing quickly, with new entrants like Netflix and Amazon.com disrupting traditional networks. The Motley Fool's new free report, "Who Will Own the Future of Television?" details the risks and opportunities in TV. Click here to read the full report!

3 Stocks to Get on Your Watchlist

I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated. Without my watchlist, I'd be unable to keep up on my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time came to choose which stock I'm buying or shorting next.

Today is Watchlist Wednesday, so I'm discussing three companies that have crossed my radar in the past week -- and at what point I may consider taking action on these calls with my own money. Keep in mind that these aren't concrete buy or sell recommendations, nor do I guarantee I'll take action on the companies being discussed. What I can promise is that you can follow my real-life transactions through my profile and that I, like everyone else here at The Motley Fool, will continue to hold the integrity of our disclosure policy in the highest regard.

Exelixis (NASDAQ: EXEL  )
Yesterday was a big day for Exelixis shareholders, as it gave them their first glimpse of Cometriq sales. Designed for the treatment of metastatic medullary thyroid cancer, or MTC -- a rare but particularly aggressive form of thyroid cancer -- Cometriq, which is Exelixis' first drug approved by the Food and Drug Administration, nearly tripled progression-free survival in trials relative to AstraZeneca's (NYSE: AZN  ) Caprelsa, the current standard of treatment (11.2 months compared to four months). Based on those stats alone, I expect Cometriq to take practically all sales from AstraZeneca in MTC.

Exelixis' first-quarter results released last night -- a $0.24 loss per share on $9.7 million in sales -- handily surpassed Wall Street's expectations, which had called for a loss of $0.29 per share on $5.3 million in revenue. However, only $1.9 million in sales was because of Cometriq. I can't say that I'm disappointed with this initial figure, but I'm not exactly jumping for joy, either.

Looking down the road, Exelixis shareholders have few catalysts this year aside from growing Cometriq's total sales. Next year is when things will get really interesting as Cometriq appeared to show significant efficacy in reducing metastatic bone tumors. If that proves true in trials currently being run with regard to castration-resistant prostate carcinoma, metastatic renal cell cancer, and metastatic hepatocellular carcinoma, then Exelixis could take off in 2014 when top-line data for some of these studies is revealed. I remain steadfast that Exelixis is a candidate for a big run higher moving forward.

Odyssey Marine Exploration (NASDAQ: OMEX  )
I love a good metals play as much as any Fool around here, but Odyssey Marine is certainly not on the buy list. Odyssey Marine is a salvage company that searches for, recovers, and monetizes metals and minerals found on the ocean floor. Make no mistake about it, the job is as cool as it sounds; unfortunately, "cool" doesn't always translate into solid profits.

As my Foolish colleague Rich Duprey recently noted, a myriad of issues has been weighing down Odyssey's share price, including a decline in metals prices and, more important, an order to turn over some $500 million worth of gold and silver coins recovered from the 1804 shipwreck of the Nuestra Senora de las Mercedes to the Spanish government. Rich, however, sees positives in Odyssey Marine's mineral operations and thinks it could make an intriguing, but speculative, play as metal prices recover. As for me, I'd look for short-selling opportunities into any rally.

The concern I have with Odyssey Marine's business model is that it's based on high discovery costs, a copious amount of regulations (i.e., Spain's gold and silver reclamation), and is completely based on luck. There is absolutely no consistency in results from one quarter to the next, which can have a huge bearing on the company's cash flow and outlook. You may get lucky enough to hit this stock before a major find, but I'd suggest betting against it on any significant rallies until it develops a steadier revenue stream.

SolarCity (NASDAQ: SCTY  )
You know how I'm a staunch advocate for profitability?... Well, throw that out the window just this once!

SolarCity is a relatively newly traded solar company that sells or leases solar panels to residential and commercial customers. The prospect of leasing solar panels might seem idiotic at first until you realize just how expensive the purchase and installation of those panels can be. Once SolarCity makes its initial purchasing investment in the panels, it frees the company to set up recurring monthly revenue leasing streams. The best part is the costs from the consumer and business end could actually wind up dropping over the long run as standard fuel costs rise.

Best Investments In 2014

SolarCity also hasn't needed to advertise out the hilt. In fact, it's utilizing a similar marketing ploy to that used by Tupperware, which is to allow residential customers to set up in-home parties and gatherings that show off the uses of the product. Apparently this strategy must be working, as revenue grew by 22% in the fourth quarter as the total number of customers (presumedly residential) rose by 192%. While losses will be the name of the game for probably the next few quarters, I would be very intrigued to dig even deeper into SolarCity on any major pullback. 

Foolish roundup
Is my bullishness or bearishness misplaced? Share your thoughts in the comments section below, and consider following my cue by using these links to add these companies to your free, personalized Watchlist to keep up on the latest news with each company:

Add Exelixis to My Watchlist. Add Odyssey Marine Exploration to My Watchlist. Add SolarCity to My Watchlist.

Looking for more commodities-based ideas? Download the free report "The Tiny Gold Stock Digging Up Massive Profits." The Motley Fool's analysts have uncovered a little-known gold miner they believe is poised for greatness; find out which company it is and why its future looks bright -- for free!

2 Numbers That Can Help Separate The 'Buys' From The 'Sells'

In recent years, investors have been steadily pouring billions into exchange-traded funds (ETFs). The appeal of investing in an industry or thematic style is a simpler approach than stock-picking for many investors.

Yet there are still many investors looking for the most appealing stocks in any given sector. But finding the right stock can be tricky if they all seem to be similarly valued or all are poised to profit from the same trend.

I was thinking about this topic recently as I checked in with the nation's leading auto suppliers. Four months ago, I noted that all of the major companies in this industry were capable of robust share buybacks, thanks to their prodigious cash flow. 

It's a theme that has surely resonated with other investor as well, as each of these stocks has since outperformed the S&P 500.

 

Thanks to ongoing gains, these auto parts suppliers don't look quite as cheap as they once did, with all sporting double-digit price-to-earnings (P/E) multiples. But if you own several of them and would prefer to hang on to only one stock in an industry, there's a way to identify the true value. And it is a more accurate gauge than the use of a simple P/E ratio. It involves a bit of leg work, but is worth the trouble. Better still, it can be applied to almost industry -- not just auto parts suppliers.

What's A Dollar Of Sales Worth?
Make no mistake, a dollar of sales generated by Microsoft (Nasdaq: MSFT) is worth much more than a dollar of sales generated by auto parts suppliers (or any other manufacturing firm). Fully 34 cents out of every sales dollar ends up as operating profit for Microsoft, which makes it one of the highest profit margin generators in the world. 

In contrast, let's look at the three-year average operating profit margin for auto parts suppliers.

Clearly, the profit margins in various car components tend to vary, whether you are talking about seats, dashboard, airbags, bumpers, etc. TRW (NYSE: TRW) is clearly able to generate premium pricing for its safety systems that are being used in more high-end cars and trucks. BorgWarner (NYSE: BWA) is now benefiting from its heavy past investments in state-of-the-art transmissions. 

As these two firms are clearly the most profitable, each dollar of sales should be perceived as more valuable by investors (since more of that dollar flows to the bottom line). Let's look at the enterprise value, in relation to 2012 sales, for each of these firms to see if that's true.

For the most part, these stocks sport enterprise-value-to-sales (EV/sales) ratios that seem to reflect their profit margin profiles. With 10% operating margins, three times higher than industry laggard Dana Holdings, Borg-Warner's EV/sales ratio is less than twice as high, which suggests its stock is relatively undervalued. 

This kind of analysis is most helpful when companies have similar margin profiles or EV/sales ratios. Note that Magna International's (NYSE: MGA) EV/sales ratio is just above the ratio sported by Dana Holdings, yet Magna's operating margins are 67% higher. In this instance, Magna is clearly the better buy. And if you own both stocks, each of which has gained roughly 18% in the past four months, then Dana is the better sell candidate. 

You can also use these metrics in paired trade scenarios, by going long the most undervalued -- relative to its operating margin structure -- while shorting the most overvalued one. 

Risks to Consider: It's crucial to track ongoing changes in profit margins, as they may be a sign that an industry leader is losing its pricing advantage or that an industry laggard is getting its act together.

Action to Take --> You can apply this logic to almost any industry, from medical-device makers and banking stocks to software providers. The apples-to-apples comparisons of financial metrics for companies operating in the same industry can tell you a lot more about valuation than just the P/E ratio.

P.S. -- What if your portfolio had an 85% win rate, clocked annualized returns as high as 510%, and you only had to spend 12 minutes per month managing it? Amy Calistri's Stock of the Month advisory is doing just that for thousands of investors right now. Click here to see how.

10 Best Oil Stocks To Watch Right Now

You can't read the news lately without some mention of the current domestic energy boom. The U.S. is producing more oil than it has in a long time, and as a result we are importing less oil than we have in decades. Today, I'm going to take a closer look at five charts to show what it is exactly we are importing, where it comes from, where it goes, and what our energy import future really looks like.

1. Imports by type
Unless explicitly referred to as crude oil, when we read about "oil imports" the number tossed about often includes refined petroleum products such as diesel, jet fuel, and gasoline. Though the overwhelming majority of our oil imports are in fact comprised of crude oil, we do import significant quantities of refined products. In March, crude oil imports were about 7.6 million barrels per day, while products imports came to about 1.8 million barrels per day. The chart below shows the types of products and relative quantities that made up the bulk of our petroleum imports last year, not including crude oil.

10 Best Oil Stocks To Watch Right Now: Weatherford International Ltd(WFT)

Weatherford International Ltd. provides equipment and services used in the drilling, evaluation, completion, production, and intervention of oil and natural gas wells worldwide. It offers artificial lift systems, which include reciprocating rod lift systems, progressing cavity pumps, gas lift systems, hydraulic lift systems, plunger lift systems, hybrid lift systems, wellhead systems, and multiphase metering systems. The company also provides drilling services, including directional drilling, ?Secure Drilling? services, well testing, drilling-with-casing and drilling-with-liner systems, and surface logging systems; and well construction services, such as tubular running services, cementing products, liner systems, swellable products, solid tubular expandable technologies, and inflatable products and accessories. In addition, it designs and manufactures drilling jars, underreamers, rotating control devices, and other pressure-control equipment used in drilling oil and nat ural gas wells; and offers a selection of in-house or third-party manufactured equipment for the drilling, completion, and work over of oil and natural gas wells for operators and drilling contractors, as well as a line of completion tools and sand screens. Further, the company provides wireline and evaluation services; and re-entry, fishing, and thru-tubing services, as well as well abandonment and wellbore cleaning services; stimulation and chemicals, including fracturing and coiled tubing technologies, cement services, chemical systems, and drilling fluids; integrated drilling services; and pipeline and specialty services. It serves independent oil and natural gas producing companies. The company was founded in 1972 and is headquartered in Geneva, Switzerland.

Advisors' Opinion:

• [By Tom Bishop]

  Weatherford International (WFT) is trading around $14. Weatherford is a leading provider of equipment and services to the oil and gas industry, based in Switzerland. These shares have traded in a range betwe en $10.85 to $26.25 in the last 52 weeks. The 50-day moving average is $15.46 and the 200-day moving average is $19.62. WFT is estimated to earn about 88 cents per share in 2011 and $1.67 for 2012. Analysts at UBS set a $28 price target for WFT share.

10 Best Oil Stocks To Watch Right Now: Williams Partners L.P.(WPZ)

Williams Partners L.P. focuses on natural gas transportation, gathering, treating and processing, storage, natural gas liquid fractionation, and oil transportation activities in the United States. The company operates in two segments, Gas Pipeline, and Midstream Gas and Liquids. The Gas Pipeline segment owns and operates approximately 13,900 miles of pipelines with annual throughput of approximately 2,700 trillion British thermal units of natural gas and delivery capacity of approximately 13 million dekatherms of gas. This segment also owns interests in joint venture interstate and intrastate natural gas pipeline systems. The Midstream Gas and Liquids segment includes natural gas gathering, processing, and treating facilities; and crude oil gathering and transportation facilities that serve the producing basins in Colorado, New Mexico, Wyoming, the Gulf of Mexico, and Pennsylvania. Williams Partners GP LLC serves as the general partner of the company. Williams Partners L.P . was founded in 2005 and is based in Tulsa, Oklahoma.

Advisors' Opinion:

• [By Louis Navellier]

  Williams Partners (NYSE:WPZ) is an integrated natural gas company that is involved with exploration and production, midstream gathering and processing and interstate natural gas transportation. In the last nine-and-a-half months, WPZ stock has gained 18% since January 2011.

5 Best Stocks To Buy For 2014: Worthington Energy Inc (WGAS.PK)

Worthington Energy, Inc. (Worthington), formerly Paxton Energy, Inc., incorporated July 30, 2004, is an oil and gas exploration and production company with assets in Texas and in the Gulf of Mexico. Worthington�� assets in Texas consist of a minority working interest in limited production and drilling prospects in the Cooke Ranch area of La Salle County, Texas, and Jefferson County, Texas, all operated by Bayshore Exploration L.L.C. (Bayshore). The Company�� assets in the Gulf of Mexico consist of a leasehold working interests in certain oil and gas leases located offshore from Louisiana, upon which no drilling or production has commenced as of December 31, 2011, and a 10.35% interest in the recently drilled I-1 well and a 2% royalty interest in 14,400 acres in the Mustang Island Tract 818. On March 27, 2012, it acquired certain assets from Black Cat Exploration & Production, LLC.

In Texas, the Company has working interests ranging from 4% to 31.75% (ne t revenue interests ranging from 3% to 23.8125%) in the various wells. In the Gulf of Mexico it has a 70% leasehold working interest, with a net revenue interest of 51.975%, of certain oil and gas leases in the Vermillion 179 tract and 10.35% interest in the recently drilled I-1 well and a 2% royalty interest in 14,400 acres in the Mustang Island Tract 818. As of December 31, 2011, it had one producing well that generated average total monthly net revenue.

The Mustang Island 818-L Field, located in the Kleberg County waters of the Gulf of Mexico, is a field re-habilitation project targeting bypassed or only partially produced gas-condensate. Total production from the wells within the seismic coverage was 125.6 billion cubic feet. In January 2011, the Hercules Offshore 205 jack-up rig was contracted to re-enter the I-Well on the Mustang License Area. The oil and gas leases are located in the VM 179, which is in the shallow waters of the Gulf of Mexico offshore fr om Louisiana. VM 179 is at 85 inches water depth approxima! te! ly 46 miles offshore Louisiana in the Gulf of Mexico.

10 Best Oil Stocks To Watch Right Now: Caiterra International Energy Corp (CTI)

CaiTerra International Energy Corporation (Caiterra), formerly Cyterra Capital Corp., is a Canada-based company is engaged in the exploration and development of oil and gas properties. The Company�� project includes Faust, Amadou and Lac La Biche. On March 9, 2012, the Company completed its qualifying transaction with West Pacific Petroleum Inc. (WPP), pursuant to which the Company acquired all of WPP�� working interests in certain petroleum and natural gas leases and an oil sand lease in the Lac La Biche and Amadou Projects located in Alberta, Canada and certain other assets (the QT Oil and Gas Properties) from West Pacific Petroleum Inc. (WPP). On December 17, 2012 the Company acquired the Faust Property located just north of the Swan Hills oil field and south of the Town of Slave Lake.

10 Best Oil Stocks To Watch Right Now: ATP Oil And Gas Corp (ATPO.MU)

ATP Oil & Gas Corporation, incorporated in 1991, is engaged in the acquisition, development and production of oil and natural gas properties. As of December 31, 2011, the Company had estimated net proved reserves of 118.9 Million barrels of crude oil equivalent (MMBoe), of which approximately 75.9 MMboe (64%) were in the Gulf of Mexico and 42.9 MMBoe (36%) were in the North Sea. The reserves consisted of 78.6 Million barrels (MMBbls) of oil (66%) and 241.5 billion cubic feet (Bcf) of natural gas (34%). Its proved reserves in the deepwater area of the Gulf of Mexico account for 62% of the Company�� total proved reserves and its proved reserves on the Gulf of Mexico Outer Continental Shelf account for 2% of its total proved reserves. During the year ended December 31, 2011, the Company acquired three licenses in the Mediterranean Sea covering potential natural gas resources in the deepwater off the coast of Israel (East Mediterranean). On August 17, 2012, ATP Oil And Ga s Corp filed for Chapter 11 bankruptcy protection.

The Company�� natural gas reserves are split between the Gulf of Mexico (57%) and the North Sea (43%). Of its total proved reserves, 8.3 MMBoe (7%) were producing, 19.0 MMBoe (16%) were developed and not producing and 91.6 MMBoe (77%) were undeveloped. The Company�� average working interest in its properties at December 31, 2011, was approximately 81%. The Company operates 92% of its platforms. At December 31, 2011, in the Gulf of Mexico, it owned leasehold and other interests in 38 offshore blocks and 49 wells, including 23 subsea wells. The Company operates 43 (88%) of these wells, including 100% of the subsea wells. In the North Sea, it also had interests in 13 blocks and two Company-operated subsea wells. As of March 15, 2011, the Company owned an interest in 13 platforms, including two floating production facilities in the Gulf of Mexico, the ATP Titan at its Telemark Hub and the ATP Innovator at its G omez Hub. It operates the ATP Innovator and the ATP Titan.!

10 Best Oil Stocks To Watch Right Now: Stone Energy Corporation(SGY)

Stone Energy Corporation, an independent oil and natural gas company, engages in the acquisition, exploration, exploitation, development, and operation of oil and gas properties in the Gulf of Mexico and the Appalachia region. As of December 31, 2010, it had estimated proved oil and natural gas reserves of approximately 473.9 billion cubic feet of gas equivalent. The company was founded in 1993 and is headquartered in Lafayette, Louisiana with additional offices in New Orleans, Louisiana; Houston, Texas; and Morgantown, West Virginia.

Advisors' Opinion:

• [By Matthews]

  Stone Energy (SGY) is trading at $19.88. Stone is an oil and gas drilling company with projects in the Gulf of Mexico, Appalachia, and Texas. These shares have traded in a range between $14.21 to $35.94 in t he last 52 weeks. The 50-day moving average is $24.54 and the 200-day moving average is $27.49. SGY is estimated to earn $3.58 per share in 2011 and $3.64 in 2012. In terms of PE ratios, this appears to be one of the cheapest oil stocks in the market. In July, Dahlman Rose set a $38 price target for SGY shares and Ladenburg Thalmann has a $30 target.

10 Best Oil Stocks To Watch Right Now: Marathon Petroleum Corp (MPC)

Marathon Petroleum Corporation (MPC), incorporated on November 9, 2009, is a petroleum product refiners, transporters and marketers in the United States. The Company operates in three segments: Refining & Marketing, Speedway and Pipeline Transportation. Marathon Petroleum�� refining, marketing and transportation operations are concentrated in the Midwest, Gulf Coast and Southeast regions of the United States. MPC has two retail brands: Speedway and Marathon. Effective as of June 30, 2011, MPC was separated from Marathon Oil Corporation (Marathon Oil) and became an independent company in a spin-off transaction.

Refining & Marketing

The Company owned and operated six refineries in the Gulf Coast and Midwest regions of the United States with an aggregate crude oil refining capacity of approximately 1.2 million barrels per calendar day as of December 31, 2011. During 2011, its refineries processed 1,177 million barrels per day of crude oil and 181 mbpd of other charge and blend stocks. Its refineries include crude oil atmospheric and vacuum distillation, fluid catalytic cracking, catalytic reforming, desulfurization and sulfur recovery units. The refineries process a range of crude oils and produce numerous refined products, ranging from transportation fuels, such as reformulated gasolines, blend-grade gasolines intended for blending with fuel ethanol and ultra-low-sulfur diesel fuel, to heavy fuel oil and asphalt. Additionally, MPC manufacture aromatics, propane, propylene, cumene and sulfur.

The Company�� Garyville, Louisiana refinery is located along the Mississippi River in southeastern Louisiana between New Orleans and Baton Rouge. The Garyville refinery is configured to process heavy sour crude oil into products, such as gasoline, distillates, asphalt, polymer grade propylene, propane, isobutane, sulfur and fuel-grade coke. The Catlettsburg, Kentucky refinery is located in northeastern Kentucky on the western bank of the Big Sandy River, near the confluence! with the Ohio River. The Catlettsburg refinery processes sweet and sour crude oils into products such as gasoline, distillates, asphalt, cumene, petrochemicals, propane and propylene. The Robinson, Illinois refinery is located in southeastern Illinois. The Robinson refinery processes sweet and sour crude oils into products, such as multiple grades of gasoline, distillates, anode-grade coke, propane, butane and propylene.

MPC�� Detroit, Michigan refinery is located near Interstate 75 in southwest Detroit. It is the petroleum refinery operating in Michigan. The Detroit refinery processes light sweet and heavy sour crude oils, including Canadian crude oils, into products, such as gasoline, distillates, asphalt, slurry, propane, and propylene. Its Canton, Ohio refinery is located approximately 60 miles southeast of Cleveland, Ohio. The Canton refinery processes sweet and sour crude oils into products such as gasoline, distillates, asphalt, propane, slurry and roofing flux. Its Texas City, Texas refinery is located on the Texas Gulf Coast approximately 30 miles south of Houston, Texas. The refinery processes sweet crude oil into products such as gasoline, chemical grade propylene, propane, slurry and aromatics.

As of December 31, 2011, the Company owned and operated 62 light product and 21 asphalt terminals. In addition, it distributes through approximately 52 third-party light product and 12 third-party asphalt terminals in its market area. During 2011, marine transportation operations included 15 towboats, as well as 167 owned and 14 leased barges that transport refined products on the Ohio, Mississippi and Illinois rivers and their tributaries, as well as the Intercoastal Waterway. As of December 31, 2011, the Company leased or owned approximately 1,950 railcars of various sizes and capacities for movement and storage of refined products. In addition, it own 124 transport trucks for the movement of refined products.

The Company produces propane at all six of its! refineri! es. Propane is primarily used for home heating and cooking, as a feedstock within the petrochemical industry, for grain drying and as a fuel for trucks and other vehicles. The Company is also a producer and marketer of feedstocks and specialty products. Product availability varies by refinery and includes propylene, cumene, dilute naphthalene oil, molten sulfur, toluene, benzene and xylene. Propane is primarily used for home heating and cooking, as a feedstock within the petrochemical industry, for grain drying and as a fuel for trucks and other vehicles.

Speedway

The Company sells transportation fuels and convenience products in the retail market in the Midwest, primarily through Speedway convenience stores. The Speedway segment sells gasoline and merchandise through convenience stores that the Companu owns and operates, primarily under the Speedway brand. Speedway-branded convenience stores offer a range of merchandise, such as prepared foods, beverages and non-food items, including a number of private-label items. As of December 31, 2011, Speedway had 1,371 convenience stores in seven states.

Pipeline Transportation

The Company transports crude oil and other feedstocks to our refineries and other locations, delivers refined products to wholesale and retail market areas and includes, among other transportation-related assets, a majority interest in LOOP LLC, which is the owner and operator of the United States deepwater oil port. It owns common carrier pipeline systems through Marathon Pipe Line LLC (MPL) and Ohio River Pipe Line LLC (ORPL), both of which are wholly owned subsidiaries. These pipeline systems transport crude oil and refined products, primarily in the Midwest and Gulf Coast regions, to its refineries, its terminals and other pipeline systems. The Company�� MPL and ORPL wholly owned carrier systems consist of 1,707 miles of crude oil lines and 1,825 miles of refined product lines comprising 31 systems located in 11 states, as of Decem! ber 31, 2! 011. In addition, MPL leases and operates 217 miles of common carrier refined product pipelines.

The common carrier refined product pipelines include the owned and operated Cardinal Products Pipeline and the Wabash Pipeline. The Cardinal Products Pipeline delivers refined products from Kenova, West Virginia, to Columbus, Ohio. The Wabash Pipeline system delivers refined products from Robinson, Illinois, to various terminals in the area of Chicago, Illinois. Other refined product pipelines owned and operated by MPL extend from: Robinson, Illinois to Louisville, Kentucky; Robinson, Illinois to Lima, Ohio; Wood River, Illinois to Indianapolis, Indiana; Garyville, Louisiana to Zachary, Louisiana, and Texas City, Texas to Pasadena, Texas.

As of December 31, 2011, the Company had partial ownership interests in the pipeline companies that have approximately 110 miles of crude oil pipelines and 3,600 miles of refined products pipelines, including about 970 miles operated by MPL, which include Centennial Pipeline LLC (Centennial), Explorer Pipeline Company (Explorer), LOCAP LLC (LOCAP), LOOP LLC (LOOP), Muskegon Pipeline LLC (Muskegon) and Wolverine Pipe Line Company (Wolverine).

The Company holds a 50% interest in Centennial, which owns a refined products pipeline system connecting the Gulf Coast region with the Midwest market. The Company holds a 17% interest in Explorer, a refined products pipeline system extending from the Gulf Coast to the Midwest. It holds a 51% interest in LOOP, the owner and operator of the Louisiana Offshore Oil Port, which is a deepwater oil port capable of receiving crude oil from large crude carriers, located 18 miles off the coast of Louisiana, and a crude oil pipeline connecting the port facility to storage caverns and tanks at Clovelly, Louisiana. The Company holds a 60% interest in Muskegon, which owns a refined products pipeline extending from Griffith, Indiana to North Muskegon, Michigan. It hold a 6% interest in Wolverine, a refined prod! ucts pipe! line system extending from Chicago, Illinois to Toledo, Ohio.

Advisors' Opinion:

• [By Jim Jubak]

   A river of oil from the oil-shale boom in North Dakota and Texas is gradually making its way to the country's Gulf Coast refineries as pipelines and other infrastructure are built out. The arrival of oil from resources like the Eagle Ford and Bakken shales will mean rising margins at Gulf Coast refineries as they begin their work with cheaper oil.

  Marathon Petroleum (MPC) will get a big hunk of that refining business -- and those higher refining margins -- and it seems determined to gather in even more with its purchase in October of BP's (BP) Texas City refinery. Texas City gives Marathon a refinery close to growing crude production from Eagle Ford and the Permian Basin. What I like about this deal -- and Marathon Petroleum's positioning -- is that as the infrastructure buildout continues, the company will be able to grow margins and earnings by simply substituting cheaper mid-continent oil for more expensive imported oil.

10 Best Oil Stocks To Watch Right Now: ATP Oil And Gas Corp (AOB)

ATP Oil & Gas Corporation, incorporated in 1991, is engaged in the acquisition, development and production of oil and natural gas properties. As of December 31, 2011, the Company had estimated net proved reserves of 118.9 Million barrels of crude oil equivalent (MMBoe), of which approximately 75.9 MMboe (64%) were in the Gulf of Mexico and 42.9 MMBoe (36%) were in the North Sea. The reserves consisted of 78.6 Million barrels (MMBbls) of oil (66%) and 241.5 billion cubic feet (Bcf) of natural gas (34%). Its proved reserves in the deepwater area of the Gulf of Mexico account for 62% of the Company�� total proved reserves and its proved reserves on the Gulf of Mexico Outer Continental Shelf account for 2% of its total proved reserves. During the year ended December 31, 2011, the Company acquired three licenses in the Mediterranean Sea covering potential natural gas resources in the deepwater off the coast of Israel (East Mediterranean). On August 17, 2012, ATP Oil And Gas Corp filed for Chapter 11 bankruptcy protection.

The Company�� natural gas reserves are split between the Gulf of Mexico (57%) and the North Sea (43%). Of its total proved reserves, 8.3 MMBoe (7%) were producing, 19.0 MMBoe (16%) were developed and not producing and 91.6 MMBoe (77%) were undeveloped. The Company�� average working interest in its properties at December 31, 2011, was approximately 81%. The Company operates 92% of its platforms. At December 31, 2011, in the Gulf of Mexico, it owned leasehold and other interests in 38 offshore blocks and 49 wells, including 23 subsea wells. The Company operates 43 (88%) of these wells, including 100% of the subsea wells. In the North Sea, it also had interests in 13 blocks and two Company-operated subsea wells. As of March 15, 2011, the Company owned an interest in 13 platforms, including two floating production facilities in the Gulf of Mexico, the ATP Titan at its Telemark Hub and the ATP Innovator at its Gomez Hub. It operates the ATP Innovator and the ATP Titan.

10 Best Oil Stocks To Watch Right Now: Linn Energy LLC (LINE)

Linn Energy, LLC (LINN Energy) is an independent oil and natural gas company. The Company�� properties are located in the United States, primarily in the Mid-Continent, the Permian Basin, Michigan, California and the Williston Basin. Mid-Continent Deep includes the Texas Panhandle Deep Granite Wash formation and deep formations in Oklahoma and Kansas. Mid-Continent Shallow includes the Texas Panhandle Brown Dolomite formation and shallow formations in Oklahoma, Louisiana and Illinois. Permian Basin includes areas in West Texas and Southeast New Mexico. Michigan includes the Antrim Shale formation in the northern part of the state. California includes the Brea Olinda Field of the Los Angeles Basin. Williston Basin includes the Bakken formation in North Dakota. On December 15, 2011, the Company acquired certain oil and natural gas properties located primarily in the Granite Wash of Texas and Oklahoma from Plains Exploration & Production Company (Plains).

On November 1, 2011, and November 18, 2011, it completed two acquisitions of certain oil and natural gas properties located in the Permian Basin. On June 1, 2011, it acquired certain oil and natural gas properties in the Cleveland play, located in the Texas Panhandle, from Panther Energy Company, LLC and Red Willow Mid-Continent, LLC (collectively Panther). On May 2, 2011, and May 11, 2011, it completed two acquisitions of certain oil and natural gas properties located in the Williston Basin. On April 1, 2011, and April 5, 2011, the Company completed two acquisitions of certain oil and natural gas properties located in the Permian Basin. On March 31, 2011, it acquired certain oil and natural gas properties located in the Williston Basin from an affiliate of Concho Resources Inc. (Concho). During the year ended December 31, 2011, the Company completed other smaller acquisitions of oil and natural gas properties located in its various operating regions. As of December 31, 2011, the Company operated 7,759 or 69% of its 11,230 gross productiv! e wells.

Mid-Continent Deep

The Mid-Continent Deep region includes properties in the Deep Granite Wash formation in the Texas Panhandle, which produces at depths ranging from 10,000 feet to 16,000 feet, as well as properties in Oklahoma and Kansas, which produce at depths of more than 8,000 feet. Mid-Continent Deep proved reserves represented approximately 47% of total proved reserves, as of December 31, 2011, of which 49% were classified as proved developed reserves. The Company owns and operates a network of natural gas gathering systems consisting of approximately 285 miles of pipeline and associated compression and metering facilities that connect to numerous sales outlets in the Texas Panhandle.

Mid-Continent Shallow

The Mid-Continent Shallow region includes properties producing from the Brown Dolomite formation in the Texas Panhandle, which produces at depths of approximately 3,200 feet, as well as properties in Oklahoma, Louisiana and Illinois, which produce at depths of less than 8,000 feet. Mid-Continent Shallow proved reserves represented approximately 20% of total proved reserves, as of December 31, 2011, of which 70% were classified as proved developed reserves. The Company owns and operates a network of natural gas gathering systems consisting of approximately 665 miles of pipeline and associated compression and metering facilities that connect to numerous sales outlets in the Texas Panhandle.

Permian Basin

The Permian Basin is an oil and natural gas basins in the United States. The Company�� properties are located in West Texas and Southeast New Mexico and produce at depths ranging from 2,000 feet to 12,000 feet. Permian Basin proved reserves represented approximately 16% of total proved reserves, as of December 31, 2011, of which 56% were classified as proved developed reserves.

Michigan

The Michigan region includes properties producing from the Antrim Shale formation in the northern ! part of t! he state, which produces at depths ranging from 600 feet to 2,200 feet. Michigan proved reserves represented approximately 9% of total proved reserves, as of December 31, 2011, of which 90% were classified as proved developed reserves.

California

The California region consists of the Brea Olinda Field of the Los Angeles Basin. California proved reserves represented approximately 6% of total proved reserves, as of December 31, 2011, of which 93% were classified as proved developed reserves.

Williston Basin

The Williston Basin is one of the premier oil basins in the United States. The Company�� properties are located in North Dakota and produce at depths ranging from 9,000 feet to 12,000 feet. Williston Basin proved reserves represented approximately 2% of total proved reserves, as of December 31, 2011, of which 48% were classified as proved developed reserves.

10 Best Oil Stocks To Watch Right Now: ConocoPhillips(COP)

ConocoPhillips operates as an integrated energy company worldwide. The company?s Exploration and Production (E&P) segment explores for, produces, transports, and markets crude oil, bitumen, natural gas, liquefied natural gas, and natural gas liquids. Its Midstream segment gathers, processes, and markets natural gas; and fractionates and markets natural gas liquids in the United States and Trinidad. The company?s Refining and Marketing (R&M) segment purchases, refines, markets, and transports crude oil and petroleum products, such as gasolines, distillates, and aviation fuels. Its Chemicals segment manufactures and markets petrochemicals and plastics. This segment offers olefins and polyolefins, including ethylene, propylene, and other olefin products; aromatics products, such as benzene, styrene, paraxylene, and cyclohexane, as well as polystyrene and styrene-butadiene copolymers; and various specialty chemical products comprising organosulfur chemicals, solvents, catalyst s, drilling chemicals, mining chemicals, and engineering plastics and compounds. The company?s Emerging Businesses segment develops new technologies and businesses. It focuses on power generation; and technologies related to conventional and nonconventional hydrocarbon recovery, refining, alternative energy, biofuels, and the environment. This segment also offers E-Gas, a gasification technology producing high-value synthetic gas. ConocoPhillips was founded in 1917 and is based in Houston, Texas.

Advisors' Opinion:

• [By Fabian]

  ConocoPhilips(COP) is a close second. This is a Warren Buffett darling that will benefit from its spinoff of refining assets some time in 2012.

  Conoco also continues to pay a consistent and reliable 3.75%. Note that COP has underperformed the rest of the sector recently. Correlations are normally so close that such an underperformance by one stock can point the way to value.

Best Penny Stocks For 2014

It's been more than three years since the spill at the Macondo well in the Gulf of Mexico, and day by day the prospects for oil exploration there seem to get better. A recent report by Wood MacKenzie shows that production in the Gulf went up 6% last year, and another 4% is expected this year. By 2018, the research group�believes�that the Gulf will be back to its pre-Macondo-spill high in�production�of 2 million barrels per day. �

For this to happen, though, exploration and production companies will need to spend a pretty penny. Between now and 2015, E&P companies are expected to spend somewhere around $20 billion. In this video, fool.com contributor Tyler Crowe looks at what this could mean for oil services companies that specialize in offshore regions such as the Gulf.

Best Penny Stocks For 2014: MCG Capital Corporation(MCGC)

MCG Capital Corporation is a private equity firm specializing in investments in middle market companies. The firm does not prefer investments in highly cyclical and volatile industry sectors and businesses with significant volatility exposure. It seeks to invest in small to mid sized companies. The firm prefers to invest in acquisitions, growth financings, organic growth, recapitalization, and leveraged buyouts. It invests in companies based in the United States. The firm seeks to invest upto $75 million in debt and equity in companies having revenues between $20 million and $200 million and EBITDA between $3 million and $25 million. It seeks to invest in the form of senior debt, including amortizing, bullet maturity, term loans, and revolving credit facilities; institutional sub debt, including junior capital; second lien debt, that includes term loans on sole source and participant basis; secured and unsecured subordinate loans structured as current interest, deferred in terest, and equity linked components; mezzanine debt and equity that includes minority equity investments. The firm may invest in minority or control equity positions. It was formerly known as MCG Credit Corporation. MCG Capital Corporation was founded in 1990 and is based in Arlington, Virginia.

Best Penny Stocks For 2014: The Cushing MLP Total Return Fund(SRV)

Cushing MLP Total Return Fund is a closed-end mutual fund launched by Swank Capital, LLC. The fund is managed by Swank Energy Income Advisors L.P. It invests in the public equity and fixed income markets across the globe with a focus in United States. The fund typically invests in MLPs, Other Natural Resource Companies, and global commodities. It primarily invests in the securities of MLPs, other equity securities, debt securities, and securities of non-U.S. issuers employing a fundamental analysis. Cushing MLP Total Return Fund was formed on May 23, 2007 and is domiciled in Dallas.

5 Best Stocks To Invest In 2014: Westell Technologies Inc.(WSTL)

Westell Technologies, Inc., through its subsidiaries, engages in the design, distribution, marketing, and servicing a range of broadband, digital transmission, remote monitoring, power distribution, and demarcation products used by telephone companies and other telecommunications service providers. It operates in three segments: Customer Networking Systems (CNS) equipment, Outside Plant Systems (OSP) equipment, and ConferencePlus services. The CNS equipment segment provides networking and high-speed transmissions products, such as modems, routers, versatile gateway devices, and wireless broadband home routers that allow service providers to deliver broadband services over existing copper, fiber, coax, or wireless infrastructures. The OSP segment offers next generation outdoor cabinets; enclosures; power distribution; fiber, Ethernet, and coax edge connectors; remote monitoring equipment; and DS1 and DS3 transmission plugs. This segment also markets and sells power distribu tion and remote monitoring solutions. The ConferencePlus services segment provides audio, Web, and video conferencing services to businesses and individuals. This segment sells its services directly to Fortune 1000 companies, and indirectly through its private reseller programs. The company offers its products through field sales organizations and selected distributors in the United States, as well as in Canada and Europe. Westell Technologies, Inc. was founded in 1980 and is headquartered in Aurora, Illinois.

Best Penny Stocks For 2014: Advanced Cell Technology, Inc.(ACTC)

Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. Its embryonic stem cell research programs include cellular reprogramming, reduced complexity program, and stem cell differentiation research programs. The company?s cellular reprogramming involves in the development of therapies based on the use of genetically identical pluripotent stem cells generated by its cellular reprogramming technologies. Advanced Cell Technology, Inc. also generates stable cell lines with particular focus on blood lineage and vascular epithelial cell lines from hemangioblast cells. In addition, it is developing an autologous myoblast transplantation therapy to restore cardiac function in patients with advanced heart disease. The company?s stem cell-based therapy would provide treatment for a range of acute and chronic degenerative diseases. Further, it deve lops adult stem cell-based products that are specifically targeted at therapies for heart and other cardiovascular diseases. The company is headquartered in Marlborough, Massachusetts.

Advisors' Opinion:

• [By Michael J. Ray]

  Any speculative biotech investor who has their fingers on the pulse of the market knows of ACTC. Recent events have brought ACTC to the forefront, and now they are the tip of the spear when it comes to the new world of regenerative medicine. This all came about as Geron (GERN) made the decision to stop focusing its time and talent on stem cell research and turned their attention to their other products in their pipeline. As a result, ACTC now takes the lead in this exciting new field of medical technology.

  The question now is why would I classify it as a “Time Bomb”? The reason for this is simple if one were to think about it. The purpose of the “time bomb” is to explode at a future date and cause massive damage, and that is what ACTC is going to do. The real question is what is going to get damaged? If all goes well with the current clinical trial for Stargardt’s macular dystrophy and dry age-related macular degeneration, and ACTC can prove its revolutionary technology works, then the “time bomb” will cause massive damage to the current standards of medical care and the companies that they represent. ACTC’s stem cell technologies will quickly become mainstream and common place around the world as its products can now starts to address unmet medical needs. Established medical companies will quickly be attempting to form partnerships or joint ventures with ACTC to get ahead of the curve and support their income streams. These stem cells will be used to treat macular degeneration, chronic heart failure, advanced cardiac disease, cardiovascular disease, as well as generate clean and safe blood products. This is just a handful of ailments that ACTC states that they can address. Waiting in the wings are more exciting ideas that have yet to be fully discussed.

  If all does not go well with the current trials then the “time bomb” will have an equally destructive affect on the current investors. ACTC’s future rests on their stem! cell technologies. There is no fallback position or other product in the pipeline to save them if the trials go wrong. Their Phase 1/2 clinical trial for Stargardt’s macular dystrophy and dry age-related macular degeneration is going to be the key for the company. Its pivotal results will either usher in a paradigm shift in medicine or set the stem cell investment world back many years.

  The final question is when will the “time bomb” will go off? Unfortunately the answer to that question is not known, but any investor can clearly hear the ticking getting louder and louder as the final moment arrives for the dramatic conclusion. These ticks come in the form of bits of useful information that tell investors that the time is almost up. Here are just some of the “ticks” that investor are hearing.

• [By Sy_Harding]

  Advanced Cell Technology Inc. (OTC: ACTC)is up 1.52% to $0.181 on volume of 10.46 million shares. ACTC, a biotechnology company applying cellular technology in the field of regenerative medicine, today announced the UCLA IRB approval of itsphase 1/2 clinical trialsusing hESC-derived RPE cells for the treatment of macular degeneration. (OTC:ACTC), (ACTC)

Top 10 Medical Companies To Own In Right Now

Willie Nelson, who turned 80 on April 30, once sang a song about an alarm clock that rang two hours late, a garbage man who spilled all the trash on the sidewalk, hinges that were falling off the gate, spilling his coffee, and having his wife leave him -- all on the same day. Some health-care stocks might need their own country songs after the past few days. Here are three of the most horrendous health-care stocks over the last week.

The way isn't greener
Lowering guidance doesn't tend to help a stock very much. Greenway Medical Technologies (NYSE: GWAY  ) found that out this week, with shares plunging more than 23%.

Greenway doesn't report its quarterly results until next week, but the electronic health record systems vendor decided to let the cat out of the bag early. The company projects revenue for the fiscal year ending June 30 of $132 million to $134 million. That range is lower than the $145 million to $150 million Greenway expected less than three months ago.

Top 10 Medical Companies To Own In Right Now: Cell Therapeutics Inc (CTIC)

Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.

Pixuvri

As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.

OPAXIO

OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.

Tosedostat

In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.

Brostallicin

As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).

The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.

Top 10 Medical Companies To Own In Right Now: Organovo Holdings Inc (ONVO.PK)

Organovo Holdings, Inc. (Organovo), formerly Real Estate Restoration & Rental, Inc., incorporated in 2007, is a development-stage company. The Company has developed and is commercializing a platform technology for the generation of three-dimensional (3D) human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. On December 28, 2011, Real Estate Restoration and Rental, Inc.�� (RERR) entered into an Agreement and Plan of Merger, pursuant to which RERR merged with its, wholly owned subsidiary, Organovo (Merger Sub). On February 8, 2012, the Company merged with and into Organovo Acquisition Corp. (Acquisition Corp.), a wholly owned subsidiary of Organovo, with the Company surviving the merger as a wholly owned subsidiary of Organovo Holdings (the Merger). As a result of the Merger, Organovo acquired the business of Organovo, Inc.

The C ompany has collaborative research agreements with Pfizer, Inc. (Pfizer) and United Therapeutic Corporation (Unither). As of March 31, 2012, it has five federal grants, including Small Business Innovation Research grants and developed the NovoGen MMX Bioprinter (its first-generation 3D bioprinter). The Company is engaged in the development of specific 3D human tissues to aid Pfizer in discovery of therapies in two areas of interest. In addition, in October 2011, it entered into a research agreement with Unither to establish and conduct a research program to discover treatments for pulmonary hypertension using its NovoGen MMX Bioprinter technology. Additionally, under the research agreement with Unither, the Company granted Unither an option to acquire from the Company a worldwide, royalty-bearing license in certain intellectual property created under the research agreement solely for use in the treatment or prevention of pulmonary hypertension and all other lung diseases.

The Company�� NovoGen MMX Bioprinter is an aut! om! ated device that enables the fabrication of three-dimensional (3D) living tissues comprised of mammalian cells. A custom graphic user interface (GUI) facilitates the 3D design and execution of scripts that direct precision movement of the dispensing heads to deposit cellular building blocks (bio-ink) or supporting hydrogel. The Company is using a third party manufacturer, Invetech Pty., of Melbourne, Australia, to manufacture its NovoGen MMX Bioprinter. Its bioprinting technology and surrounding intellectual property and commercial rights serve as a platform for product generation across multiple markets that employ cell- and tissue-based products and services.

The Company competes with Organogenesis, Advanced BioHealing, Tengion, Genzyme, HumaCyte and Cytograft Tissue Engineering.

Best Stocks For 2014: Galena Biopharma Inc (GALE)

Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). On January 19, 2012, the Company initiated enrollment in its Phase 3 PRESENT clinical trial for NeuVax (E75 peptide plus GM-CSF) vaccine in low-to-intermediate HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment study is a randomized, multicenter, multinational clinical trial that will enroll approximately 700 breast cancer patients. The Company�� Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival (DFS). On April 13, 2011, the Company completed its acquisition of Apthera, Inc.,(Apthera).

The Company focuses to start a Phase 2 trial comparing NeuVax in combination with trastuzumab (Herceptin) versus trastuzumab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting. The Company's second product candidate, Folate Binding Protein-E39 (FBP), is a vaccine, consisting of the peptides E39 and J65, aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. On February 14, 2012, the Company announced the initiation of a Phase 1/2 clinical trial in two gynecological cancers: ovarian and endometrial adenocarcinomas. Folate binding protein has ! very limited tissue distribution and expression in non-malignant tissue and is over-expressed in more than 90% of ovarian and endometrial cancers, as well as in 20% to 50% of breast, lung, colorectal and renal cell carcinomas.

In April 2011, the Company acquired Apthera Inc and its NeuVax product candidate. The Company focuses on developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide, the advanced of which is NeuVax, which is targeted at preventing the recurrence of breast cancer. NeuVax has had positive Phase 1/2 clinical trial results for the prevention of breast cancer recurrence in patients who have had breast cancer and received the standard of care treatment (surgery, chemotherapy, radiotherapy and hormonal therapy as indicated). The Company had also initiated its Phase 3 PRESENT clinical trial of NeuVax for the prevention of breast cancer recurrence in early-stage low-to-intermediate HER2 breast cancer patients. NeuVax directs killer T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. NeuVax is comprised of a HER2/neu-derived peptide called E75. E75 is a nine-amino acid sequence that is immunogenic (produces an immune response) and GM-CSF is a commercially available protein that acts to stimulate and activate components of the immune system such as macrophages and dendritic cells.

The Company also develops novel applications for NeuVax based on preclinical studies and phases 2 clinical trials which suggest that combining NeuVax and trastuzumab (Herceptin; Genentech/Roche) can increase antigen presentation by tumor cells by promoting receptor internalization and subsequent proteosomal degradation of the HER2 protein. The Company also is pursuing additional therapeutic indications for NeuVax that are in Phase 1/2 clinical trials. RXI-109, is a dermal anti-scarring therapy that targets! connecti! ve tissue growth factor (CTGF) and that may inhibit connective tissue formation in human fibrotic disease.

The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc., GlaxoSmithKline plc, Renovo Group plc, CoDa Therapeutics, Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene, Derma Sciences, Inc., Healthpoint Biotherapeutics, Pharmaxon, Excaliard Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris.

Top 10 Medical Companies To Own In Right Now: Terumo (TRUMY.PK)

TERUMO CORPORATION operates in four business segment. The Hospital Products segment is engaged in the manufacture, purchase and sale of hospital medical equipment, pharmaceuticals, peritoneal dialysis and diabetes related products, and the rental of hospital medical equipment and home medical products. The Cardiac and Vascular Area segment is involved in the manufacture, purchase and sale of catheter systems, artificial heart and lungs, as well as artificial blood vessels, the manufacture and sale of therapeutic coils for cerebral aneurysm, sampling equipment and kits for platelet-rich plasma and concentrated bone-marrow cell, and large-bore sheaths. The Blood System segment is engaged in the manufacture, purchase and sale of blood transfusion-related products. The Healthcare segment manufactures and sells healthcare related products. As of March 31, 2012, the Company had 79 subsidiaries and 2 associated companies. Advisors' Opinion:

• [By Robert Holmes]

   Analyst Mayo Mita says the Japanese earthquake and tsunami was a setback for the company, Terumo has a more visible growth stage coming.

  "Over the next five years we see clear growth from China, the NOBORI drug eluting stent (DES), the U.S. catheter business, and the blood management business," Mita writes.

  The base-case Mita lays out is for a 26% rise in share price next year, although Mita's most bullish forecast has shares up twice that. On the downside, Mita's most bearish scenario has shares falling 11% in the next 12 months.

  The chart below shows shares of Terumo that trade on the Pink Sheets in the U.S., but Morgan Stanley is recommending buying shares in Tokyo.

Top 10 Medical Companies To Own In Right Now: Myriad Genetics Inc (MYGN)

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).

As of June 30, 2012, the Company had launched nine commercial molecular diagnostic tests. The Company markets these tests through its own approximate 385-person sales force in the United States. The Company also markets its BRACAnalysis, COLARIS, and COLARIS AP tests through its own European sales force and have entered into marketing collaborations with other organizations in selected Latin American, European and Asian countries. The Company also generates revenue by providing companion diagnostic services to the pharmaceutical, and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology.

Molecular Diagnostic Tests

The Company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels and proteins to assess an individual's risk for developing disease later in life, determine a patient's likelihood of responding to a particular drug, assess a patient's risk of disease progression and disease recurrence and measure a patient's exposure to drug therapy to ensu! re optimal dosing and reduced drug toxicity. The Company's BRACAnalysis test is a analysis of the BRCA1 and BRCA2 genes for assessing a woman's risk of developing hereditary breast and ovarian cancer. BRACAnalysis accounted for 81.7% of the Company's total revenue during the fiscal year ended June 30, 2012. Its The Company's COLARIS test is an analysis of the MLH1, MSH2, MSH6 and PMS2 genes for assessing a person's risk of developing colorectal cancer or uterine cancer.

The Company's COLARIS AP test detects mutations in the APC and MYH genes, which cause a colon polyp-forming syndrome known as Familial Adenomatous Polyposis (FAP), a more common variation of the syndrome known as attenuated FAP, and the MYH-associated polyposis signature (MAP). The Company's MELARIS test analyzes mutations in the p16 gene to determine genetic susceptibility to malignant melanoma. The Company's OnDose test is a nanoparticle immunoassay that is designed to assist oncologists in optimizing 5-FU (fluorouracil) anti-cancer drug therapy in colon cancer patients on an individualized basis. The Company's PANEXIA test is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. The Company's PREZEON test is an immunohistochemistry test that analyzes the PTEN gene and assesses loss of PTEN function in many cancer types.

The Company's Prolaris test is a 46-gene molecular diagnostic assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that can be safely monitored through active surveillance, or a more aggressive form of the disease that would warrant aggressive intervention, such as a radical prostatectomy or radiation therapy. The Company's TheraGuide 5-FU test analyzes mutations in the DPYD gene and variations in the TYMS gene to assess patient risk of toxicity to 5-FU (fluorouracil) anti-cancer drug therapy.

Companion Diagnostic Services and Other Revenue

! Through M! yriad RBM Inc., the Company provides biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical researches industries utilizing its multiplexed immunoassay technology. The Company's technology enables the Company to screen large sets of clinical samples from both diseased and non-diseased populations against the Company's menu of biomarkers. The Company's companion diagnostic services consist of Multi-Analyte Profile (MAP), Multiplexed Immunoassay Kits and TruCulture.

The Company has compiled a library of over 550 individual human and rodent immunoassays for use in its multi-analyte profile (MAP) testing services. The Company has also developed RodentMAP, a panel for use in pre-clinical animal studies and OncologyMAP, which measures cancer-related proteins to assists researchers accelerate the pace of discovery, validation and translation of cancer biomarkers for early detection, patient stratification and therapeutic monitoring. The Company has developed multiplexed immunoassay kits that enable its customers to leverage its technology services with their in-house capabilities. The Company's internally developed multiplexed immunoassay kits include all of the components necessary for a customer to perform a test on their own Luminex instrument. TruCulture is a simple, self-contained whole blood culture that can be deployed to clinical sites around the world for acquiring cell culture data without specialized facilities or training.

Top 10 Medical Companies To Own In Right Now: Cerus Corporation(CERS)

Cerus Corporation, a biomedical products company, engages in the development and commercialization of the INTERCEPT Blood System. The company?s INTERCEPT system is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. It markets the INTERCEPT system for platelets and plasma primarily in Europe, the Russian Federation, and the Middle East. The company is also developing INTERCEPT Blood System for red blood cells or red blood cell system, which is designed to inactivate blood-borne pathogens in donated red blood cells for transfusion. Cerus Corporation has collaboration agreements with Baxter International, Inc.; and BioOne Corporation, as well as the United States Armed Forces. The company was founded in 1991 and is based in Concord, California.

Advisors' Opinion:

• [By Michael Shulman]

  Cerus (NASDAQ: CERS) developed and markets the INTERCEPT Blood System, which is designed to inactivate blood-borne pathogens in blood components so the blood can be used in transfusions. In other words, it “cleans” donated blood of viruses, bacteria and parasites.

  Cerus is pretty much the only game in town with this remarkable technology, and it has gained approval in most large European countries. Why not the United States? Well, management has not stood up to the FDA. The approval has been held up by one member of the FDA even though Cerus hit the primary endpoints in its pivotal Phase III trial and is receiving grants from the Department of Defense.

  The FDA should quit dragging its feet eventually. There is no scientific or product risk in this stock. Their system works. My target price is $14 in one to three years.

Top 10 Medical Companies To Own In Right Now: Organovo Holdings Inc (ONVO)

Organovo Holdings, Inc. (Organovo), formerly Real Estate Restoration & Rental, Inc., incorporated in 2007, is a development-stage company. The Company has developed and is commercializing a platform technology for the generation of three-dimensional (3D) human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. On December 28, 2011, Real Estate Restoration and Rental, Inc.�� (RERR) entered into an Agreement and Plan of Merger, pursuant to which RERR merged with its, wholly owned subsidiary, Organovo (Merger Sub). On February 8, 2012, the Company merged with and into Organovo Acquisition Corp. (Acquisition Corp.), a wholly owned subsidiary of Organovo, with the Company surviving the merger as a wholly owned subsidiary of Organovo Holdings (the Merger). As a result of the Merger, Organovo acquired the business of Organovo, Inc.

The Company has collaborative research agreements with Pfizer, Inc. (Pfizer) and United Therapeutic Corporation (Unither). As of March 31, 2012, it has five federal grants, including Small Business Innovation Research grants and developed the NovoGen MMX Bioprinter (its first-generation 3D bioprinter). The Company is engaged in the development of specific 3D human tissues to aid Pfizer in discovery of therapies in two areas of interest. In addition, in October 2011, it entered into a research agreement with Unither to establish and conduct a research program to discover treatments for pulmonary hypertension using its NovoGen MMX Bioprinter technology. Additionally, under the research agreement with Unither, the Company granted Unither an option to acquire from the Company a worldwide, royalty-bearing license in certain intellectual property created under the research agreement solely for use in the treatment or prevention of pulmonary hypertension and all other lung diseases.

The Company�� NovoGen MMX Bioprinter is an automate! d device that enables the fabrication of three-dimensional (3D) living tissues comprised of mammalian cells. A custom graphic user interface (GUI) facilitates the 3D design and execution of scripts that direct precision movement of the dispensing heads to deposit cellular building blocks (bio-ink) or supporting hydrogel. The Company is using a third party manufacturer, Invetech Pty., of Melbourne, Australia, to manufacture its NovoGen MMX Bioprinter. Its bioprinting technology and surrounding intellectual property and commercial rights serve as a platform for product generation across multiple markets that employ cell- and tissue-based products and services.

The Company competes with Organogenesis, Advanced BioHealing, Tengion, Genzyme, HumaCyte and Cytograft Tissue Engineering.

Top 10 Medical Companies To Own In Right Now: Scancell Holdings PLC (SCLP)

Scancell Holdings PLC is a United Kingdom-based company. The Company�� principal activity of the consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. In April 2012, the Company completed recruitment to the Phase 1 clinical trial of SCIBI. In May 2012, the Company commenced recruitment and treatment of the first patient in the second part of it Phase 1/2 clinical trial of SCIBI. The Phase 2 part of the trial is conducted in five United Kingdom centers in Nottingham, Manchester, Newcastle, Leeds, and Southampton. On August 15, 2012, the Company announced the development of a platform technology, Moditope.

Top 10 Medical Companies To Own In Right Now: InspireMD Inc (NSPR)

InspireMD, Inc., incorporated on February 29, 2008, is a medical device company. The Company is focusing on the development and commercialization of its stent platform technology, MGuard. MGuard provides embolic protection in stenting procedures by placing a micron mesh sleeve over a stent. Its initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The Company�� products include MGuard Coronary Plus Bio-Stable Mesh, MGuard Peripheral Plus Bio-Stable Mesh, MGuard Carotid Plus Bio-Stable Mesh and MGuard Coronary Plus Bio-Absorbable Drug-Eluting Mesh. Its initial MGuard Coronary products incorporated a stainless steel stent. The Company subsequently replaced this stainless steel platform with a more advanced cobalt-chromium based platform, which the Company refers to as the MGuard PrimeTM version of its MGuard Coronary. The Company operates in Germany through its wholly owned subsidiary InspireMD GmbH.

The Company focuses on applying its technology to develop additional products used for other vascular procedures, specifically carotid (the arteries that supply blood to the brain) and peripheral (other arteries) procedures. The MGuard stent is an embolic protection device based on a protective sleeve, which is constructed out of an ultra-thin polymer mesh and wrapped around the stent. The protective sleeve is comprised of a micron level fiber-knitted mesh, engineered in an optimal geometric configuration and designed for utmost flexibility while retaining strength characteristics of the fiber material.

MGuard - Coronary Applications

The Company�� MGuard Coronary with a bio-stable mesh and its MGuard Coronary with a drug-eluting mesh focuses on the treatment of coronary arterial disease. The Company�� first MGuard product, the MGuard Coronary with a bio-stable mesh, is comprised of its mesh sleeve wrapped around a! bare-metal stent. The bio-absorbability of MGuard Coronary with a drug eluting bio-absorbable mesh is intended to improve upon the bio-absorbability of other drug-eluting stents, in light of the wide surface area of the mesh and the small diameter of the fiber.

MGuard - Carotid Applications

The Company focuses on marketing its mesh sleeve coupled with a self-expandable stent for use in carotid-applications. Expandable stent is a stent that expands without balloon dilation pressure or need of an inflation balloon. This product is under development, although the Company has temporarily delayed its development until additional funding is secured.

MGuard - Peripheral Applications

Peripheral Artery Disease, also known as peripheral vascular disease, is characterized by the accumulation of plaque in arteries in the legs, need for amputation of affected joints or even death, when untreated. Peripheral Artery Disease is treated either by trying to clear the artery of the blockage, or by implanting a stent in the affected area to push the blockage out of the way of normal blood flow.

The Company competes with Abbott Laboratories, Boston Scientific Corporation, Johnson & Johnson, Medtronic, Inc., The Sorin Group, Xtent, Inc., Cinvention AG, OrbusNeich, Biotronik SE & Co. KG, Svelte Medical Systems, Inc., Reva Inc. and Stentys SA.

Advisors' Opinion:

• [By Roberto Pedone]

  InspiredMD (NSPR) is a medical device company focusing on the development and commercialization of its proprietary stent platform technology, MGuard. This stock is trading up 2.3% to $2.59 in recent trading.

  Today’s Range: $2.44-$2.65
  
  52-Week Range: $1.88-$10.16
  
  Volume: 313,000
  
  Three-Month Average Volume: 99,632

  From a technical perspective, NSPR is trending higher here right off its 50-day moving average at $2.42 with heavy upside volume. This stock has been getting heavy upside volume flows for the last few weeks, which is bullish technical action. Shares of NSPR are now quickly moving within range of triggering a major breakout trade. That trade will hit if NSPR manages to take out some near-term overhead resistance levels at $2.85 to $3 with high volume.

  Traders should now look for long-biased trades in NSPR as long as it’s trending above its 50-day at $2.42 and then once it sustains a move or close above those breakout levels with volume that hits near or above 99,632 shares. If that breakout triggers soon, then NSPR will set up re-test or possibly take out its next major overhead resistance levels at $3.55 to $4.25. This stock could even tag its 200-day at $4.80 if it breaks out soon and catches some momentum buying.

Top 10 Medical Companies To Own In Right Now: Algeta ASA (ALGETA)

Algeta ASA is a Norway-based biotechnology company engaged in the development of targeted cancer therapies based on its alpha-pharmaceutical platform. The Company�� principal product is Alpharadin for the treatment of bone metastases resulting from castration-resistant prostate cancer. The Company�� pipeline also includes Alpharadin for the treatment of bone metastases resulting from breast cancer, a combination of Alpharadin with Taxotere for the treatment of bone metastases resulting from prostate cancer and Thorium-227 showing various cancer indications. The Company develops Alpharadin in a development and marketing cooperation with Bayer Schering Pharma. Algeta ASA is active through the two wholly owned subsidiaries, Algeta Innovations AS and Algeta UK Limited. On April 12, 2012, the Company announced that it estabilished a subsidiary active in the United States, Algeta US.